Menu
Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 12
An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease
Authors Mulaw Belete T
Received 8 October 2020
Accepted for publication 4 December 2020
Published 14 December 2020 Volume 2020:12 Pages 203—212
DOI https://doi.org/10.2147/CPAA.S284809
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Arthur Frankel
Tafere Mulaw Belete
Department of Pharmacology, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
Correspondence: Tafere Mulaw Belete Tel +251 918045943
Email [email protected]
Abstract: Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has a great potential to overwhelm the world healthcare systems that may lead to high morbidity and mortality. It also affects world economic development in the future. Currently, no proven effective drugs or vaccines are available for the management of COVID-19 disease. The pace of normal drug development progression is unacceptable in the context of the current pandemic. Therefore, repurposing the existing drugs that were used for the treatment of malaria, Ebola, and influenza helps rapid drug development for COVID-19. Currently, several repurposing candidate drugs are in a clinical trial including, chloroquine monoclonal antibodies, convalescent plasma, interferon, and antiviral therapies. Antiviral drugs like arbidol, remdesiv and favirnavir are the most promising due to the similarities of the viruses regarding viral entry, fusion, uncoating, and replication. This review article provides an overview of the potential therapeutic agent, which displayed better clinical treatment outcomes. Moreover, with further understanding of the SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise, and investigations on these novels anti-SARSCoV- 2 agents are also reviewed.
Keywords: corona virus, SARS-CoV-2, SARS-CoV, COVID-19, chloroquine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.